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Neurodegenerative diseasesNetwork-oriented analysis is essential to identify those parts of a cell affected by a given perturba-
tion. The effect of neurodegenerative perturbations in the form of diseases of brain metabolism was
investigated by using a newly reconstructed brain-speciﬁc metabolic network. The developed
stoichiometric model correctly represents healthy brain metabolism, and includes 630 metabolic
reactions in and between astrocytes and neurons, which are controlled by 570 genes. The integra-
tion of transcriptome data of six neurodegenerative diseases (Alzheimer’s disease, Parkinson’s
disease, Huntington’s disease, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia) with
the model was performed to identify reporter features speciﬁc and common for these diseases,
which revealed metabolites and pathways around which the most signiﬁcant changes occur. The
identiﬁed metabolites are potential biomarkers for the pathology of the related diseases. Our model
indicated perturbations in oxidative stress, energy metabolism including TCA cycle and lipid metab-
olism as well as several amino acid related pathways, in agreement with the role of these pathways
in the studied diseases. The computational prediction of transcription factors that commonly regu-
late the reporter metabolites was achieved through binding-site analysis. Literature support for the
identiﬁed transcription factors such as USF1, SP1 and those from FOX families are known from the
literature to have regulatory roles in the identiﬁed reporter metabolic pathways as well as in the
neurodegenerative diseases. In essence, the reconstructed brain model enables the elucidation of
effects of a perturbation on brain metabolism and the illumination of possible machineries in which
a speciﬁc metabolite or pathway acts as a regulatory spot for cellular reorganization.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Neurodegenerative diseases are disorders associated with func-
tional loss of brain cells, especially with advancing age. Reported
increase in the average life expectancy throughout the world
means a large increase in the number of people with these diseases
in the coming decades [1–3], making it essential to understandhow these diseases develop. A full understanding of the mecha-
nisms of neurodegenerative diseases will lead to improvement of
successive treatment techniques.
Metabolism has an essential role in the cell, therefore, it is of
substantial importance to perform a systematic investigation of
the effect of neurodegenerative diseases on brain metabolism.
Such an analysis can also reveal the common pathways perturbed
by neurodegenerative diseases as well as disease-speciﬁc meta-
bolic pathways. Limited research has been performed on this, how-
ever, a systematic and comparative analysis is still missing [4,5].
Such an analysis necessitates a detailed and curated representation
of metabolic reactions occurring in the brain. Consequently, brain-
speciﬁc metabolic stoichiometric models have recently been
reconstructed [6–8]. These models can be used as scaffolds for
computational analyses to draw hypotheses, as done for other
metabolic systems in literature [9,10].
M. Sertbas et al. / FEBS Open Bio 4 (2014) 542–553 543In this study, we have developed a novel brain-speciﬁc stoichi-
ometric metabolic model which covers a large number of meta-
bolic pathways in and between astrocytes and neurons, the two
major cell types in the brain. We then used this model as a scaffold
to analyze transcriptional changes associated with six common
neurodegenerative diseases: Alzheimer’s disease (AD), Parkinson’s
disease (PD), Huntington’s disease (HD), multiple sclerosis (MS),
amyotrophic lateral sclerosis (ALS), and schizophrenia (SCH). The
changes induced by these diseases on brain metabolism at the
transcriptional level were systematically and comparatively
analyzed by integrating corresponding transcriptome data of the
diseases with the here-developed metabolic network of brain. This
enabled a comprehensive analysis of the effect of neurodegenera-
tion on metabolism from the perspective of different related
diseases.
2. Results
2.1. Validation of the reconstructed model
We have reconstructed a novel brain metabolic model based on
a previous study [6] by (i) transforming the lumped reactions in
the original model into elementary reactions and (ii) adding new
literature-supported pathways, as described in detail in Methods
section. The new brain model comprises 630 reactions (571 inter-
nal, 59 exchange) and 524 metabolites (465 internal, 59 external).
This means a 3-fold increase in the number of reactions compared
to the original model [6]. 253 of the reactions occur in neurons
while 299 of them are astrocytic. 59 reactions are for the exchange
of metabolites, and there are 19 reactions depicting the transfer of
metabolites between the two cell types. The model is available
both in excel format and in SBML format as a supplement (Supple-
mentary Files 1 and 2). 460 out of 571 internal reactions have gene
information obtained from HumanCyc [11]. Due to the high cover-
age (81%) of gene-associated reactions in the model, it is possible
to use this brain model for the integrated computational analysis
of brain metabolism and transcriptome data. Since the total num-
ber of genes in the model is 570, it was named iMS570. Some of the
reactions are controlled by one or more genes whereas some of
the reactions do not have gene information. The number of the
matched genes is 496 (87%) covering 447 of 571 internal reactions
for GEO: GSE26927 dataset used in this study.
Note that the present model, iMS570, was developed purely in a
brain-speciﬁc manner. Its gene coverage is much higher than the
other gene-associated brain metabolic model (iNL403) reported
in literature so far (570 vs. 403) [7], which was derived from a gen-
eric human metabolic reconstruction. The curation of the present
model was achieved in extensive iterative steps such that it can
be used in ﬂux-balance based simulations. Flux balance analysis
[12] of resting healthy brain metabolism performed with the newly
reconstructed model iMS570 revealed a meaningful ﬂux distribu-
tion consistent with experimental major ﬂux splits in central
metabolism (Table 1). Similar to the original model [6], the rest-
ing-state ﬂuxes were calculated using two consecutive simula-
tions: (i) linear programming with the objective function of
maximization of the sum of these ﬂuxes through glutamate/gluta-
mine/GABA cycles (primary objective), (ii) after ﬁxing the value of
the sum of these three cycle ﬂuxes to the optimum value, quadratic
programming with the objective function of minimization of the
Euclidean norm of ﬂuxes (secondary objective). The primary objec-
tive provides a tight coupling between the two cell types, and it
was shown to outperform several other alternative objective func-
tions [6]. On the other hand, linear objective functions usually
result in non-unique ﬂux distributions, known as the problem of
alternate optima [13]. Our secondary objective function eliminatesthe alternate optima, resulting in a unique ﬂux distribution [6].
Both of the objective functions have physical meanings. The ﬁrst
one ensures a tight coupling of astrocytes and neurons through
the well-known intercellular cycles [14,15]. The second one
ensures channeling of ﬂuxes through all pathways with minimal
use of enzymes [16,17]. The FBA-based prediction of metabolic
ﬂuxes at resting state when combined with a proper objective
function is one of the superiority of the iMS570 model over the
other comprehensive brain model available in literature [7].
Besides, the FBA results render a veriﬁcation of the reconstructed
model.
The model was reconstructed in such a way that pathways
which are of major importance to brain metabolism are included.
Although there are still reactions/pathways not covered by
iMS570, we have performed an additional analysis to show that
missing reactions will not affect current results and conclusions.
To this aim, we removed 72 reactions from iMS570 belonging to
the purine and pyrimidine nucleoside metabolisms, and repeated
the reporter metabolite and reporter metabolism calculations for
PD. Among about 40 associated reporter metabolites (Table 2), only
three (astrocytic ADP, ATP and GTP) were not captured in this
highly reduced model. Additionally, only methionine metabolism
(Table 3) was not any more a reporter metabolism in addition to
the excluded pathways. This clearly shows that pathways which
may not be included in the current reconstruction do not have
any practical effect on the conclusions made.
2.2. Reporter metabolite analysis (RMA)
The developed brain model was integrated with the transcrip-
tome data (GEO: GSE26927) [18] for a comprehensive investiga-
tion of neurodegenerative diseases of AD, PD, HD, ALS, MS and
schizophrenia. RMA was applied to the data as described in Meth-
ods section, and the reporter metabolites speciﬁc to each disease
were tabulated comparatively (Table 2). ATP and ADP in neurons
are found to be reporter metabolites in all investigated neurologi-
cal diseases together with Hc, the proton in oxidative phosphoryla-
tion. When the shared reporter metabolites for Parkinson’s disease,
Alzheimer’s disease, and amyotrophic lateral sclerosis are closely
compared (Table 2), most of them are found in oxidative phosphor-
ylation metabolism (ubiquinol, ubiquinone, cytochrome C). Several
inositol derivatives are reporter metabolites in Parkinson’s disease.
As for disease-speciﬁc reporter metabolites, ketoisovalerate
(KIV), alpha-keto-beta-methylvalerate (KMV), palmitoyl-CoA, and
malate are found to be reporter metabolites only in PD. Signiﬁcant
transcriptional changes around succinate, 5-amino-levulinate and
dimethylallyl-diphosphate are speciﬁc only to AD. Succinate plays
a role in the citric acid cycle, an energy-yielding process and the
latter two metabolites are known to take part in the biosynthesis
of secondary metabolites. S-3-hydroxy-isobutyrate, bicarbonate
and propionyl-CoA satisfy the reporter metabolites criteria only
in ALS. The reporter metabolite speciﬁc to HD is 3-phosphohydr-
oxypyruvate, which is involved in serine biosynthesis. The tran-
scriptional changes signiﬁcant only in multiple sclerosis are
around lanosterol, lathosterol, 5alpha-cholesta-7-24-dien-3beta-
ol, desmosterol, cholesterol, 24-25-dihydrolanosterol, and acetam-
idobutanal. Fumarate, oxidized and reduced glutathione, and phos-
phoenol-pyruvate are reporter metabolites solely in schizophrenia.
The disease-speciﬁc reporter metabolites are potential candidates
as biomarkers for the identiﬁcation of the corresponding diseases.
The number of common reporter metabolites for these 6 dis-
eases is shown in Fig. 1, where the diagonal cells represent a total
number of reporter metabolites for the corresponding neurological
diseases. Parkinson’s disease has the highest number of reporter
metabolites (40) compared to the other neurodegenerative dis-
eases. The lowest number of the reporter metabolites is found in
Table 1
Predicted ﬂux results in this study, in comparison to the experimental results in resting (healthy) state. Predictions by the original model [6] are also given for comparison.
% Flux ratio This study Original model Experimental
Lactate release ﬂux (r11) with respect to CMRglc 7.2 4.5 3–9
[132–135]
Glutamate/glutamine cycle ﬂux (r95) with respect to CMRglc 73.1 68.0 40–80
[14,136,137]
Relative oxidative metabolism of astrocytes (rTCA,A/rTCA,total, r25/(r25 + r69)) 33.9 35.0 30
[136,138,139]
Total lipid synthesis with respect to CMRglc 3.1 2.8 2
[140]
Total PPP ﬂux with respect to CMRglc 5.5 5.6 3–6
[141,142]
Pyruvate carboxylase ﬂux (r12) with respect to CMRglc 11.1 11.7 10
[136,138,143]
Table 2
Reporter metabolite analysis results in different neurodegenerative diseases. ‘‘+’’ sign states signiﬁcant changes with p-values less than 0.05 (reporter metabolites), and ‘‘’’ sign
represents no signiﬁcant change (A: astrocytes, N: neurons).
Metabolite AD ALS HD MS PD SCH
ADP/ATP (A) +  + + + 
ADP/ATP (N) + + + + + +
AMP (A)   +   +
AMP (N)      +
GTP (A,N)     + +
NADmit/NADHmit (A)   +   
NADmit/NADHmit (N)     + 
NADP/NADPH (A)    +  
NADPmit/NADPHmit (N)      +
CytCox (A,N) + + + + + 
CytCred (A,N) + + + + + 
Ubiquinol (A,N) + +   + 
Ubiquinone (A,N) + +   + 
Hc (A,N) + + + + + +
Pyruvate (A)     + 
Pyruvate (N)   +  + +
Fumarate (N)      +
Malate (A,N)     + 
Succinate (A,N) +     
Phosphoenol–pyruvate (A,N)      +
2-Phosphoglycerate (A,N) +     +
Bicarbonate (A)  +    
Bicarbonate (N) + +    
Serine (A)  +   + 
Serine (N)     + 
KIV (A)     + 
KMV (A)     + 
3-Phosphohydroxypyruvate (A)   +   
Acetamidobutanal (A)    +  
S-3-hydroxy-isobutyrate (A)  +    
Propionyl-CoA (A)  +    
Cholesterol (A)    +  
Desmosterol (A)    +  
Dimethylallyl_diphosphate (A) +     
Lanosterol (A)    +  
Lathosterol (A)    +  
24-25-Dihydrolanosterol (A)    +  
5Alpha-cholesta-7-24-dien-3beta-ol (A)    +  
Fatty acid (A,N) +     +
Palmitoyl-CoA (A,N)     + 
1-Acyl-sn-glycerol-3-phosphate (A,N) +     +
Myo-inositol-(1-3-4)-trisphosphate (A,N)     + 
Myo-inositol-(1-3-4-5)-tetrakisphosphate (A,N)   + + + 
Myo-inositol-(1-4)-bisphosphate (A,N)     + 
Myo-inositol-(1-4-5)-trisphosphate (A,N)   + + + 
Myo-inositol-(4)-monophosphate (A,N)     + 
Phosphatidyl-1D-myo-inositol-4-5-bisphosphate (A,N) +    + 
Oxidized glutathione (A,N)      +
Reduced glutathione (A,N)      +
5-Amino-levulinate (A,N) +     
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Table 3
Reporter pathway analysis results in different neurodegenerative diseases. ‘‘+’’ sign
states signiﬁcant changes with p-values less than 0.05 (reporter pathways), and ‘‘’’
sign represents no signiﬁcant change.
Pathway PD AD ALS HD MS SCH
Glycolysis + + + +  +
Pentose phosphate pathway   +   
TCA cycle + +  + + +
Oxidative phosphorylation and ATPase + + + + + +
Glutamate–glutamine cycle +   + + +
Ketone body metabolism +  + +  +
Creatine metabolism  + +  + +
Purine nucleoside metabolism + + + + + +
Pyrimidine nucleoside metabolism + +   + 
Gaba cycle + + + +  
Aspartate metabolism     + 
Asparagine metabolism  +  + + +
Alanine metabolism +  + +  +
Glycine–serine metabolism +  +   
Leucine metabolism +  + +  +
Valine metabolism +  + + + 
Isoleucine metabolism +  + + + 
Methionine metabolism +     
Fatty acid synthesis  +  +  
CDP-diacylglycerol biosynthesis  +    
Cholesterol synthesis     + 
Phosphatidylethanolamine metabolism    +  
Phosphatidylcholine metabolism  +  + + 
Sphingomyelin metabolism +     
Inositol metabolism + + + + + 
Reactive oxygen species pathway  +  + + +
PD 40
AD 16 28
ALS 13 13 17
HD 15 10 8 19
MS 14 10 8 14 23
SCH 7 10 4 6 4 24
PD A
D
A
LS H
D
M
S
SC
H
Fig. 1. Distributions of the common reporter metabolites for neurodegenerative
diseases.
M. Sertbas et al. / FEBS Open Bio 4 (2014) 542–553 545amyotrophic lateral sclerosis, indicating a relatively unaffected
metabolism in this disease.
The highest number of common reporter metabolites is 16 in
the investigated diseases and found to be between Parkinson’s dis-
ease and Alzheimer’s disease. In general, schizophrenia has the
lowest number of shared reporter metabolites with the other dis-
eases. This indicates that transcriptional changes taking place in
schizophrenia are quite different from the others. In fact, that
result is expected as schizophrenia is also known to be a psychiat-
ric disorder. The comparison of the common reporter metabolites
in different neurodegenerative diseases (Table 2, Fig. 1) elucidates
the effect of the transcriptional changes on brain metabolism due
to different kind of perturbations (diseases).
Fig. 2 compares the diseases (observations) and the metabolites
(variables) in a PCA bi-plot. PCA bi-plots are useful in visualizing
the relationship between observations and variables. The ﬁgure
demonstrates that ALS, SCHZ and AD exhibit relatively similar phe-
notypes in terms of reporter metabolites whereas MS and PD exhi-
bit distinct proﬁles. Additionally, metabolites which are scattered
around a disease indicate a speciﬁc role for these metabolites for
the related disease. For example, lathosterol, cholesterol, and des-
mosterol populate around MS. These metabolites are speciﬁcallysigniﬁcantly affected from the perturbation caused by MS, as also
revealed in Table 2. On the other hand, these metabolites do not
have any reporter role in diseases such as AD, ALS and SCHZ since
they are located on the opposite side of the graph.
2.3. Reporter pathway analysis (RPA)
Reporter pathway analysis was performed based on the results
of RMA to explicate the pathways signiﬁcantly affected in the per-
turbed (disease) state. The pathways having a p-value of less than
0.05 are deﬁned as reporter pathways and they involve signiﬁcant
change due to disease condition. A comparison of the reporter
pathways in Table 3 indicates that fatty acid synthesis is regulated
in both Alzheimer’s disease and Huntington’s disease signiﬁcantly.
Phosphatidylcholine metabolism is affected in Alzheimer’s disease,
Huntington’s disease, and multiple sclerosis. Creatine metabolism
is signiﬁcantly perturbed in Alzheimer’s disease, amyotrophic lat-
eral sclerosis, multiple sclerosis, and schizophrenia (Table 3). Dis-
ease-speciﬁc reporter pathways are as follows: aspartate and
cholesterol metabolisms for MS, phosphatidylethanolamine
metabolism for HD, sphingomyelin metabolism for PD, CDP-diacyl-
glycerol biosynthesis for AD and pentose phosphate pathway for
ALS. There is no unique reporter pathway for schizophrenia.
Fig. 3 compares common reporter pathways for the investigated
neurological diseases, offering a more systematic demonstration of
their effect on cell metabolism. Huntington’s disease has the high-
est number of reporter pathways (17) whereas schizophrenia has
the lowest number of the reporter pathways (11). The highest
number of common reporter pathways (12) is found between Par-
kinson’s disease and Huntington’s disease. Although the number of
the reporter metabolites in Parkinson’s disease is considerably
higher than that in Huntington’s disease, total number of reporter
pathways in Huntington’s disease is higher than that in Parkinson’s
disease. Similarly, despite having the highest number of common
reporter metabolites, Parkinson’s disease and Alzheimer’s disease
have the lowest number of common reporter pathways. These
cases show that the averaged effect of metabolites over pathways
is much more signiﬁcant than the individual effects.
2.4. Computational binding site analysis
Potential transcription factors for the studied diseases were
determined based on binding sites of genes neighboring the repor-
ter metabolites, as described in Methods. Identiﬁed over-repre-
sented motifs for each reporter metabolite for the up- and down-
regulated genes are given in detail in Supplementary File 3,
together with a lumped version of all identiﬁed motifs irrespective
of corresponding reporter metabolite for each neurodegenerative
disease. According to the results, a number of transcription factors
common in more than one disease was pinpointed, among which
are paired box (Pax), forkhead box (FOX) and Sox protein families
as well as proteins such as Krüppel-like factor (KLF) 4, Upstream
stimulatory factor (USF1) 1, and SP1.3. Discussion
3.1. Energy metabolism
According to the RMA and RPA results, energy-related metabo-
lisms including glycolysis, TCA cycle, oxidative phosphorylation
and ATPase, ketone body, and creatine metabolisms are signiﬁ-
cantly regulated in the neurodegenerative diseases.
Experimental studies on Parkinson’s disease showed that oxida-
tive phosphorylation does not function properly due to the reduced
activity of NADH-ubiquinone reductase (Complex I) and NADH
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Fig. 2. PCA bi-plot comparing all investigated diseases in this study. The plot is based on the Z-scores of metabolites. The relationship between the diseases and the effect of
metabolites on the diseases are visualized.
PD 16
AD 7 13
ALS 11 6 13
HD 12 10 10 17
MS 8 9 6 10 14
SCH 8 7 7 10 7 11
PD A
D
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D
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H
Fig. 3. Distributions of the common reporter pathways for neurodegenerative
diseases.
546 M. Sertbas et al. / FEBS Open Bio 4 (2014) 542–553cytochrome c reductase [19–21]. Indeed NADH was detected to be
a reporter metabolite for PD in our analysis (Table 2). Mitochon-
drial studies of multiple sclerosis similarly revealed decreased
activities of respiratory chain complexes I and III [22]. Succinate,
the AD-speciﬁc reporter metabolite (Table 2), was reported as a
potential biomarker for this disease [23]. The alterations in TCA
cycle observed by our computational analysis for PD and AD
(Tables 2 and 3) are in agreement with the studies showing a
decrease in the a-ketoglutarate dehydrogenase complex enzyme
due to Parkinson’s disease [24,25], as well as with the ﬁndings
reporting changes in a number of mitochondrial enzymes that
function in TCA cycle on Alzheimer’s disease [26–28]. Signiﬁcant
perturbations pinpointed by RPA in schizophrenia are supported
by studies demonstrating dysregulation of several TCA cycle
enzymes and energy metabolism [4,29,30]. Our results on HD are
in agreement with the fact that energy metabolism in Huntington’s
disease was altered because of dysfunction of oxidative phosphor-ylation pathway and TCA cycle [31,32]. The reported change in lac-
tate-to-pyruvate ratio [33] and reduced pyruvate dehydrogenase
activity [31] in HD are also compatible with the fact that neuronal
pyruvate is a reporter metabolite for this disease. Regulation of
energy metabolism through altered glycolysis, as predicted for all
the diseases except MS (Table 3), can be explained by the role
reported for Paired box (Pax) 6 protein, since its mutation leads
to abnormal glucose metabolism [34]. Indeed, this transcription
factor was predicted to have a role in HD, PD and schizophrenia
in our analysis (Supplementary File 3). The potential role of pax
family in neurodegenerative diseases is also stated in literature
[35].
Another pathway related to neurodegenerative diseases is reac-
tive oxygen species, which is an indicator of oxidative stress in the
cell. This pathway was identiﬁed to be reporter in AD, HD, MS, and
schizophrenia. It is widely known that neurodegenerative diseases
are associated with oxidative stress [36,37]. Interestingly, PD and
ALS seem to be not regulated at the transcriptional level in terms
of this pathway according to our results although the opposite
was reported in literature. Our binding-site analysis, however,
revealed FOXO3 as a regulating factor for PD and AD (Supplemen-
tary File 3), which is in accordance with the role of this protein in
oxidative stress [38,39]. Therefore, we can state that the interrela-
tion of PD with oxidative stress was not on the pathway level but
through the controlling transcription factors. Indeed, a mechanism
was suggested in PD for the link between FOXO3 and FOXF2,
another identiﬁed motif in our analysis, and neurogenesis [40]. A
number of sox family proteins were identiﬁed as potential regula-
tors in PD (Supplementary File 3). Among those, the dysregulation
of Sox2, which was also predicted as a regulator in schizophrenia,
led to oxidative stress and, hence, neurodegeneration [41,42].
Krüppel-like factor (KLF) 4, which is identiﬁed in our analysis in
all the investigated diseases except Schizophrenia (Supplementary
M. Sertbas et al. / FEBS Open Bio 4 (2014) 542–553 547File 3), have recently been assigned a role in Parkinson’s disease
through oxidative stress [43].
Creatine helps to supply energy to all cells in the body, and deﬁ-
ciencies in the creatine biosynthetic pathway lead to the malfunc-
tion of brain and various severe neurological defects [44]. Our
reporter pathway analysis points out alterations in creatine metab-
olism in different neurodegenerative diseases (AD, ALS, schizo-
phrenia), in agreement with several literature reports [45–48].
There are some studies pointing to creatine supplementation as a
potential therapeutic in neurological diseases for energy homeo-
stasis [49–51]. Similar to creatine, ketone bodies, metabolites from
another reporter pathway for some of the investigated diseases, are
also used in therapeutic strategies to provide energy [52].
3.2. Amino acid metabolism
Reporter pathway analysis indicates that amino acid metabo-
lism is affected in the case of neurodegenerative diseases. Methi-
onine metabolism is regulated only in Parkinson disease. In line
with this ﬁnding, plasma analysis of L-Dopa treated Parkinson’s
patients demonstrates a decreased level of methionine and an
increased level of homocysteine in methionine metabolism [53].
Signiﬁcant perturbation in glutamate–glutamine cycle was found
by RPA for PD, HD, MS and schizophrenia. The experimental
study performed in cerebrospinal ﬂuid stated that glutamate is
declined and glutamine level is raised notably in PD [54]. RPA
identiﬁed alterations in alanine, valine, leucine, and isoleucine
metabolisms due to Parkinson’s disease in agreement with cere-
brospinal ﬂuid studies which also revealed changes in these
amino acids, among others [55]. Similarly, in the case of Hunting-
ton’s disease, results of our reporter pathway and reporter
metabolite analyses are in accord with the literature ﬁndings
indicating increased levels of alanine, isoleucine, and glutamate
[56,57]. Alteration in valine metabolism in multiple sclerosis
observed by RPA is also supported by another experimental study
[58]. This study also reports a change in tryptophan and some
others, but these are not captured by our analysis. In schizophre-
nia, signiﬁcant perturbations observed in leucine and glutamate
metabolisms by RPA can be linked to the literature studies
reporting alterations in the levels of these amino acids, among
others [57,59].
All the above mentioned ﬁndings indicate that amino acids, the
precursors of neurotransmitters, play key roles in brain. There are
abundant evidences in literature such that complex interactions
among various amino acids and metabolites in brain support
proper functioning of metabolism, leading to a healthy state. Dis-
turbances in the levels and balance among them cause cognitive
impairments associated with many psychiatric disorders, such as
schizophrenia, and with neurological disorders, such as Parkin-
son’s, Alzheimer’s disease and many others.
3.3. Lipid and related metabolisms
The studied neurodegenerative disorders were found to cause
signiﬁcant perturbations in lipid metabolism (Tables 2 and 3).
Having an important role in nourishing brain cells, inositol
metabolism is predicted to be affected in PD, AD, HD, ALS and
MS, except schizophrenia, whereas sphingomyelin metabolism
is only affected in Parkinson disease. In PD, sphingolipid struc-
tures are altered due to interactions with alpha-synuclein protein
[60]. In Alzheimer’s disease, fatty acid synthesis, phosphatidyl-
choline metabolism, CDP-diacylglycerol biosynthesis, and inositol
metabolism are determined as reporter pathways by RPA. Inositol
metabolites are known to play a major role in transducing signals
in the nervous system [61,62]. Identiﬁcation of inositol metabo-
lism as a reporter pathway in AD is in line with literature ﬁndingstating a changed level of inositol-related compounds [63,64]. In
amyotrophic lateral sclerosis, inositol metabolism is the only
reporter pathway among the other lipid-related metabolisms.
This result is in accordance with experimental study showing
perturbed composition of inositol due to this disease [65].
Reported link between cholesterol metabolism and AD and PD
in literature could not be captured by our analysis. Cholesterol
synthesis is inﬂuenced only in multiple sclerosis according to
the RPA results. This ﬁnding is in agreement with a study, which
demonstrates a decline in cholesterol, lathosterol, desmosterol
and lanosterol in multiple sclerosis [66]. The identiﬁcation of
cholesterol precursors as MS-speciﬁc reporter metabolites points
to their potential as biomarkers for MS pathology, as suggested
by a recent experimental study [67]. Although there are similar-
ities, the effects of the different neurodegenerative diseases are
different in pathway level in the brain.
Many of the reactions in lipid metabolism are associated with
ATP, and cofactors, NADH and NADPH. ATP is a reporter metabolite
in all investigated diseases, and the cofactor NADH is a reporter in
HD and PD while NADPH is a reporter in MS and schizophrenia
(Table 3). The identiﬁcation of hubs (high connection nodes) in
the metabolic network as reporters was also stated before [10].
The binding site analysis of neighbor genes of these hub reporters
predicted many common putative regulators, some of which were
discussed in previous sections. SP1 and USF1, which are known to
regulate the genes of lipid metabolism, are also among them (Sup-
plementary File 3). USF1 is a ubiquitously expressed upstream
transcription factor with multiple roles including the regulation
of apolipoprotein E [68], an AD-risk gene and known to transport
cholesterol from astrocytes to neurons [69]. SP1 belongs to zinc-
ﬁnger protein family with widespread functions, among which is
a reported essential role in the regulation of cholesterol metabo-
lism [70]. The transcriptional activity of SP1 is known to change
in Huntington’s disease with neuroprotective role [71,72], in Alz-
heimer’s disease, [73,74] and in multiple sclerosis [75]. Similarly,
literature ﬁndings associate the upstream transcription factor 1
(USF1) with AD [68], and MS [76].4. Concluding remarks
A comprehensive stoichiometric model of brain metabolism
covering interactions in and between astrocytes and neurons was
reconstructed via an extensive literature survey. The model,
termed iMS570, has the associated gene information for each
included reaction whenever possible, with much higher gene cov-
erage compared to the only other similar brain-speciﬁc model.
After it was shown that the model correctly represents healthy
resting brain metabolism in terms of the distribution of major
ﬂuxes, we used it as a scaffold for a detailed and systematic anal-
ysis of the metabolic effects of six neurodegenerative diseases
comparatively. The identiﬁed reporter metabolites revealed parts
of brain metabolic network perturbed by these diseases at tran-
scriptional level. Such metabolites respond to the perturbations
by a change in the expression levels of the surrounding genes,
either to adjust their level into a new level or to keep their level
constant. Therefore, they are potential biomarkers for the pathol-
ogy of the related diseases, and they can be used as potential drug
targets. Major effects around energy metabolism, reactive oxygen
species and lipid metabolism were explained by common tran-
scription factors regulating the genes neighboring the reporter
metabolites. Furthermore, the identiﬁed transcription factors had
roles on neurodegeneration, strengthening the potential function-
ing of the reporter metabolites as regulatory hot spots. The results,
which are presented in the form of reporter metabolites, reporter
pathways, and putative transcription factors, present a detailed
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diseases at the level of metabolism, and can therefore be used as
basis to develop and test several hypotheses. A close clinical
inspection is needed to further elaborate on the differences in
the affected metabolic pathways observed for these neurodegener-
ative diseases.
5. Methods
5.1. Transcriptome data
Transcriptome data belonging to six neurodegenerative dis-
eases (AD, PD, HD, ALS, MS and Schizophrenia) were downloaded
from Gene Expression Omnibus (Dataset series number: GEO:
GSE26927). The dataset was originally generated by Prof. Richard
Reynolds and co-workers [18] by using Illumina BeadChip platform
for the analysis of common neuroinﬂammatory pathways in these
diseases. Disease samples are from different regions of the brain
since the most affected part of the brain is different for each dis-
ease. The downloaded dataset including 118 samples was sub-
jected to outlier analysis by using Sammon mapping [77,78]
within MATLAB 2012b. Sammonmapping is a dimension reduction
method used for high dimensional data and it helps the identiﬁca-
tion of outliers. In Sammon mapping, distance matrix between the
arrays is used in place of original data matrix. A new representa-
tion of the arrays in a lower-dimensional space is aimed by mini-
mizing the total stress with reference to the original one. This
method is performed on MATLAB with the commands of ‘pdist’ giv-
ing Euclidean distances between each pair of observations in the
data matrix, and ‘mdscale’ performing non-metric multidimen-
sional scaling on the Euclidean distances. The results of Sammon
mapping are plotted to visualize samples among replicates which
show a distinct behavior from the rest. In this way, outlier samples
are determined. The identiﬁed outlier samples were discarded
from the dataset before further analysis. One such outlier sample
for HD and MS disease sets were identiﬁed (GSE: GSM663064 for
HD, GSE: GSM663079, respectively), and two outlier samples for
schizophrenia healthy set were identiﬁed (GSE: GSM663106 and
GSE: GSM663108).
5.2. Model development
A novel brain metabolic model is developed based on a previous
study [6] by (i) expanding the lumped reactions in the original
model and (ii) adding new reactions that existed in the literature.
Transforming lumped reactions into individual reactions led to a
better representation of metabolic pathways. For example, the
number of reactions in lipid metabolism is increased about ﬁvefold
after unlumping. It is aimed to integrate transcriptome data with
the brain reaction model, and gene information controlling each
reaction is obtained from HumanCyc, (www.humancyc.org) [11].
New reactions were appended to the model in four steps: (i) Addi-
tion of reactions missing in the original model following a detailed
investigation of central carbon metabolism, (ii) Addition of path-
ways for essential and non-essential amino-acids that were not
covered in the original model, (iii) Addition of pathways which
are reported to have highly expressed controlling genes based on
the transcriptomic data of healthy brain, (iv) Addition of other
pathways which are reported to be important for brain metabo-
lism. The ultimate goal is to construct a metabolic model of brain
with a correct representation of healthy metabolism. The steps fol-
lowed from model development stage to the ﬁnal analyses are
summarized in a ﬂowchart in Fig. 4. Supplementary File 1, which
lists all reactions in iMS570, also provides a complete overview
of the model expansion by giving the reference for each reaction
in the model.5.2.1. Central carbon metabolism
A literature survey yielded few reactions related to the central
carbon metabolism which were not accounted for in the original
model [6], but included in the current model. In glycolysis, 3-phos-
phoglycerate is also produced from 1-3-biphosphoglycerate via 2-
3-Disphospho-D-glycerate without yielding ATP in both astrocytes
and neurons (r15, r16, r59, r60) [79]. In addition to the already con-
sidered NADPH dependence, NADH is also used in the production
of glutamate from alpha–ketoglutarate in astrocytes and neurons
(r90, r93) [80]. Phosphoenolpyruvate carboxykinase, transforming
oxaloacetate to phosphoenol pyruvate, is expressed in both astro-
cytes and neurons (r14, r58) [81,82]. In addition to isocitrate biosyn-
thesis, citrate is also converted to oxaloacetate and acetyl-CoA in
an ATP-dependent manner in neurons as well as astrocytes enzy-
matically (r28, r72) [83]. The conversion of citrate to oxaloacetate
and acetate is taken into account in astrocytes part of the present
brain model (r29) because citrate lyase subunit beta-like protein,
responsible for this reaction, was reported to be an astrocyte-
speciﬁc enzyme [84].
5.2.2. Amino-acid pathways
Pathways for asparagine, histidine, methionine, threonine, argi-
nine, and proline amino acids were added into the present model
following an extensive literature survey. All other amino acids
were already included in the original model [6].
Asparagine is a non-essential amino acid, and its biosynthesis is
taken into account only in neurons, since asparagine synthetase,
responsible for enzymatic biosynthesis of glutamate and aspara-
gine from glutamine and aspartate is found to be neuron-speciﬁc
(r106) [84]. Histidine, an essential amino acid, is taken up by the
brain [85] and converted into neurotransmitter histamine in neu-
rons by histidine decarboxylase (r107) [86,87]. Neurons are also
capable of synthesizing histamine N-methyltransferase, producing
S-adenosyl-L-homocysteine and methylhistamine from histamine
and S-adenosyl-L-methionine (r108) [88]. Methionine, an essential
amino acid, is taken up by the brain [85]. It is converted into cys-
teine via the transsulfuration pathway in astrocytes and neurons
(r181–r186, r189–r194) [89,90]. In this pathway, homocysteine is
formed by three reactions in series and reacts with serine to
produce cystathionine which is transformed into cysteine, alpha-
ketobutyrate (2-oxobutanoate), and ammonia. Homocysteine is
also recycled to methionine due to the activity of 5-methyltetrahy-
drofolate-homocysteine methyltransferase enzyme in the brain
(r187, r195) [91]. The conversion of alpha-ketobutyrate to propio-
nyl-CoA is thought to be active in astrocytes due to the control of
this reaction by astrocyte-speciﬁc branched-chain a-keto acid
dehydrogenase complex (r188) [84]. Threonine is an essential
amino acid and can cross the blood-brain barrier with a slow rate
compared to other amino acids [85]. Its metabolism contains only
two enzymatic reactions in the brain cells (r196–r201) [92]. First,
threonine is converted to 2-amino-3-ketobutyrate by threonine
3-dehydrogenase. Then, 2-amino-3-ketobutyrate is catabolized to
glycine and acetyl-CoA via 2-amino-3-ketobutyrate ligase. Argi-
nine is taken up by the astrocytes (r607) [93]. It is used to produce
agmatine (r446) [93,94] and ornithine [95] (r447) in astrocytes. Argi-
nine is also transferred to neurons by astrocytes to synthesize
agmatine (r453) [96], citrulline (r455) [97], and ornithine (r458)
[95]. In addition to its uptake, arginine is also produced in neurons
from aspartate and citrulline (r456–r457) [95,98,99]. Ornithine is
taken up by both cell types, besides its production in astrocytes
and neurons [100]. In the cytosol of astrocytes, pyrroline-5-carbox-
ylate, an intermediate metabolite in glutamate synthesis from
ornithine, and NADPH are degraded into proline and NADP+
(r179). In astrocytic mitochondria, proline and FAD are converted
to pyrroline-5-carboxylate and FADH2 (r180). These two proline
producing and consuming reactions are considered in only
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Fig. 4. Flowchart depicting the model development steps for iMS570 and further analyses.
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reductase-like protein and Proline dehydrogenase were stated to
be astrocyte-speciﬁc [84].
5.2.3. Active pathways based on transcriptome data
Pathways controlled by the highly expressed genes were iden-
tiﬁed based on the transcriptome data of a healthy brain. To this
aim, gene expression data of different brain regions for healthy
individuals were used (control samples of GEO: GSE26927 dataset
[18], storing the transcriptome data for 6 common neurodegener-
ative diseases). Since the aim of the present study is to develop a
general model for the whole brain, the brain model constructed
here is not region-speciﬁc. The identiﬁcation of metabolic genes
with high expression was achieved in 5 steps: (i) Genes with
expression values higher than 3-fold of the average expression val-
ues of all genes in the same transcriptome data were extracted. (ii)
Among these genes, those which are expressed in only one of the
investigated regions were discarded to minimize false positives.
(iii) Of the remaining genes, the ones associated with cellular
metabolism were identiﬁed by matching with reaction-controlling
genes from HumanCyc. (iv) Metabolic pathways corresponding to
these active genes were extracted using the information given by
HumanCyc when available. If a pathway includes many reactions,
but genes controlling only few of its reactions are found to be
active in this pathway according to transcriptome data analysis,
the related pathway was disregarded since such genes are active
probably because of different functions other than metabolic con-
trol. (v) The candidate pathways were added into the present brain
model if further support from literature was found as to the activ-
ity of the pathway in the brain. This procedure led to the involve-
ment of following pathways into the brain model: inositol,
creatine, polyamine, heme, pyrimidine and purine nucleosides.
Inositol is taken up by the brain [101]. It is used to produce
diacylglycerol, complex inositol phosphate, and phosphatidylinosi-
tol (r388–r415) [102,103]. Another important metabolismconsuming arginine and functioning in both neurons and astro-
cytes is creatine metabolism (r474–r479) consisting of ornithine
and guanidinoacetate production from glycine and arginine
[104]. Guanidinoacetate is then transformed to creatine to be used
in creatine phosphate synthesis (r475–r1476, r478–r479) [105]. Agma-
tine synthesized in neurons from arginine is converted into putres-
cine (r454) [106,107] to be utilized both in polyamine metabolism
including interconversion of precursor putrescine, spermidine,
and spermine in neurons (r467–r473) [108] and in GABA synthesis
from putrescine in astrocytes (r461–r464) [109,110]. The production
of putrescine from ornithine is neuron-speciﬁc (r459) [111] and glu-
tamate production from ornithine and alpha-ketoglutarate is
astrocyte-speciﬁc (r448–r450) [112]. The metabolism of heme, an
iron containing chemical compound, is included in the present
study in both neurons and astrocytes since it has active genes sat-
isfying our criteria and supported by literature [113,114]. Heme is
synthesized from glycine and succinyl-CoA by eight reactions in
series and degraded to bilirubin via biliverdin intermediate enzy-
matically (r480–r499) [115]. Adenosine, guanosine, uridine, and cyti-
dine are nucleosides encountered in brain metabolism and they are
mainly synthesized in liver and transported into the brain through
the blood-brain barrier [116]. These nucleosides, in addition to a
ﬁve-carbon sugar, contain the bases adenine, guanine, uracil and
cytosine, respectively. These nucleosides are transformed into
related nucleotides in the brain, which are utilized in metabolic
processes or recycled to their nucleosides (r500–r571) [116].
5.2.4. Addition of other pathways
Pathways for ketone body metabolism, cardiolipin and sphingo-
myelin were included in the present model due to their importance
for brain metabolism.
Acetoacetate and 3-hydroxybutyrate are the most important
ketone bodies in human brain energy metabolism. They are pro-
duced by liver and transported by blood to brain where they can
be used in ATP production as an alternative to glucose [117]. The
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are very small in comparison with glucose in resting condition;
however, they signiﬁcantly change in case of starvation in which
uptake rates of ketone bodies increase with a decline in glucose
uptake rate [118]. Acetoacetate and 3-hydroxybutyrate are con-
verted into acetyl-CoA (r438–r444, r127–r128, r164) which participates
in TCA cycle reactions or other metabolic reactions both in astro-
cytes and neurons [119]. Cardiolipin is a phospholipid and found
in the mitochondrial membrane [120]. It is synthesized from
CDP-diacylglycerol and Glycerol-3-phosphate by three enzymatic
reactions in series in the brain (r366–r371) [121]. Sphingomyelin, a
type of sphingolipid, is localized in the brain [120,122]. Precursors
of sphingomyelin synthesis are serine and palmitoyl-CoA. Astro-
cytes use its own serine; however, neurons utilize serine trans-
ported from astrocytes in sphingomyelin synthesis since there is
no serine synthesis in neurons (r372–r376, r378–r382) [123–125].
Sphingomyelin biosynthesis includes ﬁve metabolic reactions with
3-dehydrosphinganine, sphinganine, dihydroceramide, and cera-
mide as the intermediate metabolites. Sphingomyelin is also con-
verted to ceramide and phosphoryl-choline due to the
availability of sphingomyelinase in the brain (r377, r383) [126].
5.3. Flux balance analysis
The model was validated by applying ﬂux balance analysis [12]
for the prediction of major ﬂux splits in the resting (healthy) state.
Simulations were performed in MATLAB 2012b environment. Opti-
mization (linear programming and quadratic programming) was
performed using MATLAB bindings of CPLEX ILOG optimization
algorithms provided by IBM’s Academic Initiative Program. The
healthy-case FBA simulation was performed using the exact con-
straints as reported for the original model [6], as well as few other
following constraints. The uptake rates for newly added amino
acids were constrained as 0.0025 [85], 0.0017 [85], 0.0008 [85],
0.0020 [127], and 0.0031 [85] in units of lmole/g tissue/min for
histidine, methionine, threonine, arginine and ornithine, respec-
tively. Uptake rates of ketone bodies acetoacetate and 3-hydrox-
ybutryrate were constrained to be zero since this pathway is
known to be inactive in resting state [118].
5.4. Reporter metabolite analysis
Reporter metabolites are deﬁned as metabolites around which
the most signiﬁcant transcriptional changes occur in response to
a genetic or environmental perturbation, including diseases
[10,128]. In this way, alterations in a metabolic network are eluci-
dated at the transcriptional level. For this, genes are assigned p-val-
ues based on the differential transcriptome data using t-test. p-
value of each gene (pi), representing the signiﬁcance of differential
gene data, is transformed into Z score (Zi) by using the inverse nor-
mal cumulative distribution. Then, each metabolite in the meta-
bolic network in question is scored based on the aggregated Z-
scores of the genes controlling the reactions in which the metabo-
lite is involved, i.e., each metabolite is assessed by the Z-scores of
these k neighbor genes.
Zmetabolite ¼ 1ﬃﬃﬃ
k
p
Xk
i¼1
Zi ð1Þ
In the case where a reaction is associated with more than one
gene, the one with most signiﬁcant change is taken into account
[10]. Then, Z scores are corrected by using mean (lk) and standard
deviation (rk) of the aggregated Z scores of many sets of randomly
selected k genes from the metabolic network.
Zcorrectedmetabolite ¼
ðZmetabolite  lkÞ
rk
ð2ÞIn the last step, corrected Z scores are converted to p-values,
and metabolites having p-values less than the selected cut-off are
named as reporter metabolites. For reporter metabolite analysis
(RMA), p-value of 0.05 was selected as cut-off. Those metabolites
with only a single neighbor gene were not considered as reporter
metabolites in evaluating the results. RMA calculation was per-
formed using the online BioMet Toolbox [129] ttest2 command of
Statistics Toolbox of MATLAB was used to calculate p-values based
on two-sample t-test.
5.6. Reporter pathway analysis
A novel analysis, termed reporter pathway analysis (RPA), was
performed to predict signiﬁcantly affected metabolic pathways
due to the investigated diseases with the primary goal of making
it easier to analyze RMA results. Here, each pathway is scored based
on the p-values of its metabolites, calculated through RMA. The
scoring is based on Eqs. (1) and (2), leading to pathway p-values.
The pathways having p-values less than the selected cut-off (0.05)
are deﬁned as reporter pathways, i.e., pathways signiﬁcantly
affected due to the perturbation. Calculationswere performed using
BioMet Toolbox [129]. Note that we hereby opted for a global net-
work-centered effect of the diseases on pathways by using metabo-
lite p-values to calculate pathway scores since metabolite p-values
include information on the interactions with other pathways.
5.7. Computational binding site analysis
To investigate whether genes associated with a reporter metab-
olite are controlled by common transcription factors, computa-
tional binding site analysis was performed. For each reporter
metabolite, its neighboring genes were grouped into two sets with
respect to up- and down-regulation [10]. For the sets with at least
4 gene members, DNA sequence regions with 950 to +50 base
pairs were scanned from the JASPAR database [130] for the signif-
icantly over-represented motifs of the stored transcription factors
(p-value: 0.05). The analysis was performed using the internet-
based software tool, Pscan [131].
5.8. Principal component analysis (PCA)
Metabolites which did not show a signiﬁcant change in any of
the studied diseases (p-value cut-off: 0.05) were discarded from
the set. Z-scores of the remaining metabolites were used in the
PCA analysis. The analysis was performed using pca function of Sta-
tistical Toolbox of MATLAB.
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